Drug-price worries don't stop with cancer

Oncologists aren't the only doctors rejecting high-priced drugs, Forbes columnist John LaMattina says. New diabetes and obesity drugs may falter because they have cheaper alternatives, and even rare-disease drugs may see some pushback on price. Report